{
  "id": [
    "26894975"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "26894975"
  ],
  "pmcid": [
    "PMC4924747"
  ],
  "doi": [
    "10.18632/oncotarget.7409"
  ],
  "title": [
    "Therapeutic siRNA for drug-resistant HER2-positive breast cancer."
  ],
  "authorString": [
    "Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, Gray JW, Yantasee W."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Gu S"
          ],
          "firstName": [
            "Shenda"
          ],
          "lastName": [
            "Gu"
          ],
          "initials": [
            "S"
          ],
          "authorId": [
            {
              "_": "0000-0003-2271-0524",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "affiliation": [
            "Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Hu Z"
          ],
          "firstName": [
            "Zhi"
          ],
          "lastName": [
            "Hu"
          ],
          "initials": [
            "Z"
          ],
          "affiliation": [
            "Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Ngamcherdtrakul W"
          ],
          "firstName": [
            "Worapol"
          ],
          "lastName": [
            "Ngamcherdtrakul"
          ],
          "initials": [
            "W"
          ],
          "affiliation": [
            "PDX Pharmaceuticals, LLC, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Castro DJ"
          ],
          "firstName": [
            "David J"
          ],
          "lastName": [
            "Castro"
          ],
          "initials": [
            "DJ"
          ],
          "affiliation": [
            "PDX Pharmaceuticals, LLC, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Morry J"
          ],
          "firstName": [
            "Jingga"
          ],
          "lastName": [
            "Morry"
          ],
          "initials": [
            "J"
          ],
          "affiliation": [
            "Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Reda MM"
          ],
          "firstName": [
            "Moataz M"
          ],
          "lastName": [
            "Reda"
          ],
          "initials": [
            "MM"
          ],
          "affiliation": [
            "Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Gray JW"
          ],
          "firstName": [
            "Joe W"
          ],
          "lastName": [
            "Gray"
          ],
          "initials": [
            "JW"
          ],
          "affiliation": [
            "Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA."
          ]
        },
        {
          "fullName": [
            "Yantasee W"
          ],
          "firstName": [
            "Wassana"
          ],
          "lastName": [
            "Yantasee"
          ],
          "initials": [
            "W"
          ],
          "affiliation": [
            "PDX Pharmaceuticals, LLC, Portland, Oregon, 97239, USA."
          ]
        }
      ]
    }
  ],
  "authorIdList": [
    {
      "authorId": [
        {
          "_": "0000-0003-2271-0524",
          "$": {
            "type": "ORCID"
          }
        }
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "12"
      ],
      "volume": [
        "7"
      ],
      "journalIssueId": [
        "2410865"
      ],
      "dateOfPublication": [
        "2016 Mar"
      ],
      "monthOfPublication": [
        "3"
      ],
      "yearOfPublication": [
        "2016"
      ],
      "printPublicationDate": [
        "2016-03-01"
      ],
      "journal": [
        {
          "title": [
            "Oncotarget"
          ],
          "ISOAbbreviation": [
            "Oncotarget"
          ],
          "medlineAbbreviation": [
            "Oncotarget"
          ],
          "NLMid": [
            "101532965"
          ],
          "ESSN": [
            "1949-2553"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2016"
  ],
  "pageInfo": [
    "14727-14741"
  ],
  "abstractText": [
    "HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines. We provided evidence that the drug-resistant cancer maintains dependence on HER2 for survival. Importantly, cell lines did not readily develop resistance following extended treatment with HER2 siRNA. Using our recently developed nanoparticle platform, systemic delivery of HER2 siRNA to trastuzumab-resistant tumors resulted in significant growth inhibition. Moreover, the optimal HER2 siRNA could also silence an exon 16 skipped HER2 splice variant reported to be highly oncogenic and linked to trastuzumab resistance."
  ],
  "affiliation": [
    "Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA."
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "Journal Article"
      ]
    }
  ],
  "grantsList": [
    {
      "grant": [
        {
          "grantId": [
            "HHSN261201300078C"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        },
        {
          "grantId": [
            "P50 CA058207"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        },
        {
          "grantId": [
            "U54 CA112970"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        },
        {
          "grantId": [
            "U01 CA195469"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        },
        {
          "grantId": [
            "R01 GM089918"
          ],
          "agency": [
            "NIGMS NIH HHS"
          ],
          "acronym": [
            "GM"
          ],
          "orderIn": [
            "0"
          ]
        }
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Breast cancer",
        "Nanoparticles",
        "SiRNA",
        "Her2",
        "Trastuzumab Resistance"
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC4924747?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC4924747"
          ]
        },
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "http://dx.doi.org/10.18632/oncotarget.7409"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "Y"
  ],
  "citedByCount": [
    "0"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "license": [
    "cc by"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCreation": [
    "2016-05-21"
  ],
  "dateOfRevision": [
    "2016-12-03"
  ],
  "firstPublicationDate": [
    "2016-02-15"
  ]
}